Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma

Keyphrases

• Myeloma 100%
• Immune Checkpoint Molecules 100%
• Whole-body Exposure 100%
• Programmed Death-ligand 1 (PD-L1) 80%
• Cytotoxic T-lymphocyte antigen-4 (CTLA-4) 60%
• Blocking Antibodies 60%
• Multiple Myeloma 40%
• Bone Marrow 40%
• PD-1 Blockade 40%
• CD8+ T Cells 40%
• CD4 T Cells 40%
• Tim-3 40%
• Hematological Malignancies 20%
• Tumor 20%
• Inflammatory Cytokines 20%
• T Cells 20%
• Tumor Immunity 20%
• Antitumor Efficacy 20%
• Improved Survival 20%
• Survival Rate 20%
• Drug Therapy 20%
• Novel Treatments 20%
• Successful Treatment 20%
• Faceted Approach 20%
• Incurable Disease 20%
• Checkpoint Molecules 20%
• Synergistic Antitumor 20%
• Sublethal 20%
• Combination Strategy 20%
• Myeloma Cells 20%
• Lymphodepletion 20%
• Phenotypic Analysis 20%
• Conventional Drugs 20%
• T-cell Reactivity 20%
• Observed Survival 20%
• CD48 20%
• Neoplastic Plasma Cells 20%
• TIM-3 Protein 20%

Immunology and Microbiology

• Programmed Death-Ligand 1 100%
• Low Drug Dose 100%
• Immunotherapy 100%
• Blocking Antibody 60%
• Cytotoxic T-Cell 40%
• T-Helper Cell 40%
• Survival Rate 40%
• T Cell 40%
• Multiple Myeloma 40%
• Proinflammatory Cytokine 20%
• Tumor Immunity 20%
• Myeloma Cell 20%
• Immunoglobulin Producing Cell 20%
• CD48 20%
• Cytokine 20%
• Drug Therapy 20%